Peptides against cancer (L-11627/11964) .: NR16-174/2017E-PDF
“NRC has developed peptides with novel anti-angiogenic properties that are effective against many different stimulators of angiogenesis. The NRC peptides exhibit direct anti-tumorogenic properties against different types of tumors and have been validated in vivo. The antiangiogenic activity against multiple stimulators, combined with the direct inhibition of tumour growth, position these peptides as promising treatments against malignant tumours”--Highlights.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.847576&sl=0
| Department/Agency | National Research Council Canada. |
|---|---|
| Title | Peptides against cancer (L-11627/11964) . |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Format | Electronic |
| Electronic document | |
| Note(s) | Issued also in French under title: Peptides contre le cancer (L-11627/11964). Caption title. "December 2017." Issued also in print format. |
| Publishing information | [Ottawa] : National Research Council Canada, [2018] |
| Description | [1] p. |
| ISBN | 9780660239583 |
| Catalogue number |
|
| Subject terms | Neovascularization inhibitors Peptides |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.- Date modified: